CLAIMS

1. Use of a tungsten (VI) salt or a solvate thereof, in the manufacture of a medicament for favoring normal reproduction and fertility in a non-diabetic female mammal, or for improving the efficacy of an assisted reproductive technique in a mammal.

2. The use of a tungsten (VI) salt according to Claim 1, wherein the mammal is a human.

3. The use of a tungsten (VI) salt according to Claim 1 or Claim 2, wherein said salt is manufactured to be administered in a daily dose of between 0.001 mg and 1000 mg of tungsten (VI) salt per kg of body weight of the mammal.

4. The use of a tungsten (VI) salt according to any one of Claims 1 to 3, wherein said salt comprises a tungsten (VI) anion and a pharmaceutically, veterinary or dietetically acceptable cation.

5. The use of a tungsten (VI) salt according to any one of Claims 1 to 4, wherein the cation is an alkaline or alkaline earth cation.

6. The use of a tungsten (VI) salt according to any one of Claims 1 to 5, wherein the cation is selected from the group consisting of sodium, potassium, magnesium, calcium and zinc.

7. The use of a tungsten (VI) salt according to Claim 6, wherein the cation is sodium.

8. The use of a tungsten (VI) salt according to Claim 6, wherein the cation is zinc.

9. The use of a tungsten (VI) salt according to any one of Claims 1 to 8, wherein the tungsten (VI) anion is selected from WO_4^{2-}, HWO_4^-, $W_2O_7^{2-}$ and $HW_2O_7^-$ ions.

10. The use of a tungsten (VI) salt according to Claim 9, wherein the anion is WO_4^{2-}.

11. The use of a tungsten (VI) salt according to any one of Claims 1 to 10, wherein the solvate is dihydrate.

12. The use of a tungsten (VI) salt according to any one of Claims 1 to 11, wherein the mammal is selected from the group of mammals that require restoring and/or promoting ovulation, improving oocyte or embryo quality, increasing zygote implantation on the uterine wall, regulating hypothalamic-pituitary axis impairment, including polycystic ovarian syndrome, metabolic syndrome, hyperprolactinemia, endometriosis, hypothyroidism, multiple sclerosis, rheumatoid arthritis, lupus erythematosus, cirrhosis, rheumatoid arthritis, celiac

disease, chronic kidney failure, idiopathic causes and eating disorders, such as anorexia nervosa and bulimia.

13. Use of a composition comprising a tungsten (VI) salt or a solvate thereof, at a concentration equal to or greater than 100 mg/kg and at least one pharmaceutically, veterinary or dietetically acceptable excipient or vehicle, in the manufacture of a medicament for favoring normal reproduction and fertility in a non-diabetic female mammal, or for improving the efficacy of an assisted reproductive technique applied to a mammal.

14. The use of a composition according to Claim 13, wherein the excipient or vehicle is pharmaceutically or veterinary acceptable, and the composition is a pharmaceutical composition in the manufacture of a medicament for increasing the efficacy of an assisted reproductive technique applied to a mammal.

15. The use of a composition according to Claim 13 or Claim 14, wherein the medicament is in the form of a pill, tablet, pastille, capsule, powder, wafer, effervescent powder or tablets, solution, suspension, syrup or granules.

16. Use of a composition comprising a tungsten (VI) salt or a solvate thereof, at a concentration equal to or greater than 100 mg/kg and at least one pharmaceutically, veterinary or dietetically acceptable excipient or vehicle, in the manufacture of a food composition for favoring normal reproduction and fertility in a non-diabetic female mammal.

17. The use of a composition according to Claim 16, wherein the composition is a liquid composition or a beverage.

18. The use of a composition according to Claim 16, wherein the composition is a solid composition.

19. The use of a composition according to Claim 16 or Claim 17, wherein the food composition is a nutritional supplement or complement.

20. The use of a composition according to any one of Claims 13 to 19, wherein the composition comprises sucrose.